MicroRNA is the Nobel-winning master regulator of the genome – researchers are learning to treat disease by harnessing how it controls genes
Oklahoma death row inmate had three 'last meals.' He's back at Supreme Court in new bid for freedom
Supreme Court rejects appeal from Texas officer convicted in killing of woman through her window
Israel can't confirm death of Hezbollah's Safieddine, spokesperson says
Britain withdraws family members of embassy staff from Israel
Ex-Philippine President Duterte to run as mayor despite his drug killings legacy
Global money market funds draw large inflows in the week to Oct. 2
Greece's growth seen nearly unchanged in 2025, draft budget shows
Jets QB Rodgers dealing with a low ankle sprain, but Saleh says he should be fine to play
Sean Combs’ mother says she’s ‘devastated and profoundly saddened’ by allegations against him
Ravens claim wild overtime victory, Texans snatch last-second win and Jayden Daniels keeps rolling: NFL Week 5 Sunday review
TOKYO (Reuters) - Japanese drugmaker Eisai is developing a dementia treatment that it aims to commercialise in the U.S. by fiscal 2030, the Nikkei reported on Sunday.
The new drug targets a protein called tau, which causes symptoms of Alzheimer's disease, the newspaper reported.
Eisai already has a dementia drug on the U.S. market called Leqembi, co-developed with U.S. peer Biogen.
The companies announced on Friday that they would start Leqembi sales in China, making that country the third where the treatment is available after the U.S. and Japan.
(Reporting by Kevin Buckland; Editing by Christopher Cushing)
